Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1 |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic cancer |
| ICD-0-3 | C25 |
| Methods | qPCR, Western blot, in vitro knockdown |
| Sample | PC cell lines (SW 1990, COLO357,MIA PaCa-2, T3M4, AsPC-1, BxPC-3, CAPAN-1 and PANC-1) |
| Expression Pattern | down-regulated |
| Function Description | Loss of MEG3 expression was observed in both the cancerous tissues and cancer cell lines. Although the absence of expression of MEG3 was not statistically correlated to either histological grade or TNM stage in the 25 cases, the prognosis was significantly worse. MEG3 knockdown enhanced cell proliferation, promoted cell migration and invasion, induced epithelial mesenchymal transition (EMT), increased the sphere-forming ability and cancer stem cell (CSC) properties, and decreased the chemosensitivity to gemcitabine in-vitro. In contrast, forced expression of MEG3 resulted in a reverse effect. |
| Pubmed ID | 29328401 |
| Year | 2018 |
| Title | Long non-coding RNA MEG3 functions as a tumour suppressor and has prognostic predictive value in human pancreatic cancer. |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for pancreatic cancer | OMIM COSMIC |